Literature DB >> 21071764

Long-term follow-up high-resolution CT findings in non-specific interstitial pneumonia.

Masanori Akira1, Yoshikazu Inoue, Toru Arai, Tomohisa Okuma, Yutaka Kawata.   

Abstract

BACKGROUND: The aims of this study were to retrospectively assess the change in findings on follow-up CT scans of patients with non-specific interstitial pneumonia (NSIP; median, 72 months; range, 3-216 months) and to clarify the correlation between the baseline CT findings and mortality.
METHODS: The study included 50 patients with a histologic diagnosis of NSIP. Two observers evaluated the high-resolution CT (HRCT) findings independently and classified each case into one of the following three categories: (1) compatible with NSIP, (2) compatible with UIP or (3) suggestive of alternative diagnosis. The correlation between the HRCT findings and mortality was evaluated using the Kaplan-Meier method and the log-rank test, as well as Cox proportional hazards regression models.
RESULTS: Ground-glass opacity and consolidation decreased, whereas coarseness of fibrosis and traction bronchiectasis increased on the follow-up HRCT scans, however, in 78% of cases the overall extent of parenchymal abnormalities had no change or decreased. Patients with HRCT diagnosed compatible with NSIP had a longer survival than those with HRCT findings more compatible UIP or an alternative diagnosis. On multivariate analysis, the coarseness of fibrosis alone was associated with prognosis (HR: 1.480; 95% CIs 1.100 to 1.990).
CONCLUSIONS: The HRCT patterns seen in patients with a histopathologic diagnosis of NSIP progress in a variable manner. Overall disease extent may decrease over time in some, while fibrosis may progress in others. The initial HRCT diagnosis may impact survival in this group of patients.

Entities:  

Mesh:

Year:  2010        PMID: 21071764     DOI: 10.1136/thx.2010.140574

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  14 in total

1.  [Current classification of interstitial pulmonary diseases].

Authors:  J Vogel-Claussen; A Prasse
Journal:  Radiologe       Date:  2014-12       Impact factor: 0.635

2.  Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome.

Authors:  Hui Liu; Sheng Xie; Tian Liang; Li Ma; Hongliang Sun; Huaping Dai; Chen Wang
Journal:  Eur Radiol       Date:  2019-03-27       Impact factor: 5.315

3.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

Authors:  William D Travis; Ulrich Costabel; David M Hansell; Talmadge E King; David A Lynch; Andrew G Nicholson; Christopher J Ryerson; Jay H Ryu; Moisés Selman; Athol U Wells; Jurgen Behr; Demosthenes Bouros; Kevin K Brown; Thomas V Colby; Harold R Collard; Carlos Robalo Cordeiro; Vincent Cottin; Bruno Crestani; Marjolein Drent; Rosalind F Dudden; Jim Egan; Kevin Flaherty; Cory Hogaboam; Yoshikazu Inoue; Takeshi Johkoh; Dong Soon Kim; Masanori Kitaichi; James Loyd; Fernando J Martinez; Jeffrey Myers; Shandra Protzko; Ganesh Raghu; Luca Richeldi; Nicola Sverzellati; Jeffrey Swigris; Dominique Valeyre
Journal:  Am J Respir Crit Care Med       Date:  2013-09-15       Impact factor: 21.405

4.  Clinical profile of unclassifiable interstitial lung disease: Comparison with chronic fibrosing idiopathic interstitial pneumonias.

Authors:  Daniel Traila; Cristian Oancea; Emanuela Tudorache; Ovidiu Fira Mladinescu; Bogdan Timar; Voicu Tudorache
Journal:  J Int Med Res       Date:  2017-07-31       Impact factor: 1.671

5.  Prognostic effects of clinical and CT imaging features on critically ill patients with interstitial lung disease hospitalized in respiratory intensive care unit.

Authors:  Shenyun Shi; Yonglong Xiao; Xiaohua Qiu; Yan Li; Yuying Qiu; Kefeng Zhou; Hourong Cai
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379

6.  Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability.

Authors:  Koichiro Kamio; Arata Azuma; Ken Ohta; Yukihiko Sugiyama; Toshihiro Nukiwa; Shoji Kudoh; Tohru Mizushima
Journal:  BMC Pulm Med       Date:  2014-05-17       Impact factor: 3.317

7.  Clinical Course and Changes in High-Resolution Computed Tomography Findings in Patients with Idiopathic Pulmonary Fibrosis without Honeycombing.

Authors:  Hiroyoshi Yamauchi; Masashi Bando; Tomohisa Baba; Kensuke Kataoka; Yoshihito Yamada; Hiroshi Yamamoto; Atsushi Miyamoto; Soichiro Ikushima; Takeshi Johkoh; Fumikazu Sakai; Yasuhiro Terasaki; Akira Hebisawa; Yoshinori Kawabata; Yukihiko Sugiyama; Takashi Ogura
Journal:  PLoS One       Date:  2016-11-09       Impact factor: 3.240

8.  Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Authors:  Kevin R Flaherty; Kevin K Brown; Athol U Wells; Emmanuelle Clerisme-Beaty; Harold R Collard; Vincent Cottin; Anand Devaraj; Yoshikazu Inoue; Florence Le Maulf; Luca Richeldi; Hendrik Schmidt; Simon Walsh; William Mezzanotte; Rozsa Schlenker-Herceg
Journal:  BMJ Open Respir Res       Date:  2017-09-17

9.  Readily accessible CT scoring method to quantify fibrosis in IPF.

Authors:  Emily Fraser; Victoria St Noble; Rachel K Hoyles; Rachel Benamore; Ling-Pei Ho
Journal:  BMJ Open Respir Res       Date:  2020-06

Review 10.  Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis.

Authors:  Myriam Aburto; Inmaculada Herráez; David Iturbe; Ana Jiménez-Romero
Journal:  Med Sci (Basel)       Date:  2018-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.